Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Amer M Zeidan^#¹, Jan Philipp Bewersdorf^#², Rena Buckstein³, Mikkael A Sekeres⁴, David P Steensma⁵, Uwe Platzbecker⁶, Sanam Loghavi⁷, Jacqueline Boultwood⁸, Rafael Bejar⁹, John M Bennett¹⁰, Uma Borate¹¹, Andrew M Brunner¹², Hetty Carraway¹³, Jane E Churpek¹⁴, Naval G Daver¹⁵, Matteo Della Porta¹⁶, Amy E DeZern¹⁷, Fabio Efficace¹⁸, Pierre Fenaux¹⁹, Maria E Figueroa⁴, Peter Greenberg²⁰, Elizabeth A Griffiths²¹, Stephanie Halene²², Robert P Hasserjian²³, Christopher S Hourigan²⁴, Nina Kim²⁵, Tae Kon Kim²⁶, Rami S Komrokji²⁷, Vijay Kutchroo²⁸, Alan F List²⁷, Richard F Little²⁹, Ravi Majeti³⁰, Aziz Nazha³¹, Stephen D Nimer⁴, Olatoyosi Odenike³², Eric Padron²⁷, Mrinal M Patnaik³³, Gail J Roboz³⁴, David A Sallman²⁷, Guillermo Sanz³⁵, Maximilian Stahl³⁶, Daniel T Starczynowski³⁷, Justin Taylor⁴, Zhuoer Xie²⁷, Mina Xu³⁸, Michael R Savona²⁶, Andrew H Wei³⁹, Omar Abdel-Wahab², Valeria Santini⁴⁰

Affiliations

¹ Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA. amer.zeidan@yale.edu.
² Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
⁴ Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
⁵ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
⁶ Leipzig University Hospital, Leipzig, Germany.
⁷ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Blood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
⁹ Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, CA, USA.
¹⁰ Hematopathology Division, Departments of Pathology and Medicine, University of Rochester Medical Center, Rochester, NY, USA.
¹¹ Division of Hematology, Department of Internal Medicine, James Cancer Center, Ohio State University, Columbus, OH, USA.
¹² Leukemia Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
¹³ Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
¹⁴ Department of Hematology, Oncology, and Palliative Care, Carbone Cancer Center, The University of Wisconsin-Madison, Madison, WI, USA.
¹⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁶ Department of Biomedical Sciences, Humanitas Clinical and Research Center & Humanitas University, Milan, Italy.
¹⁷ Johns Hopkins Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD, USA.
¹⁸ Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
¹⁹ Hôpital Saint Louis, Paris, France.
²⁰ Division of Hematology, Department of Medicine, Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
²¹ Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
²² Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
²³ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
²⁴ Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
²⁵ National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
²⁶ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
²⁷ Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
²⁸ Evergrande Center for Immunologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
²⁹ Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
³⁰ Division of Hematology, Department of Medicine, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
³¹ Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
³² The University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
³³ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
³⁴ Weill Cornell Medical College, New York, NY, USA.
³⁵ Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Health Research Institute La Fe, Valencia, Spain; and CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
³⁶ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
³⁷ Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
³⁸ Departments of Pathology & Laboratory Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
³⁹ Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
⁴⁰ University of Florence Medical School, Florence, Italy.

^# Contributed equally.

PMID: 36266326
DOI: 10.1038/s41375-022-01724-9

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Amer M Zeidan et al. Leukemia. 2022 Dec.

. 2022 Dec;36(12):2939-2946.

doi: 10.1038/s41375-022-01724-9. Epub 2022 Oct 20.

Authors

Affiliations

¹ Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA. amer.zeidan@yale.edu.
² Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
⁴ Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
⁵ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
⁶ Leipzig University Hospital, Leipzig, Germany.
⁷ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Blood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
⁹ Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, CA, USA.
¹⁰ Hematopathology Division, Departments of Pathology and Medicine, University of Rochester Medical Center, Rochester, NY, USA.
¹¹ Division of Hematology, Department of Internal Medicine, James Cancer Center, Ohio State University, Columbus, OH, USA.
¹² Leukemia Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
¹³ Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
¹⁴ Department of Hematology, Oncology, and Palliative Care, Carbone Cancer Center, The University of Wisconsin-Madison, Madison, WI, USA.
¹⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁶ Department of Biomedical Sciences, Humanitas Clinical and Research Center & Humanitas University, Milan, Italy.
¹⁷ Johns Hopkins Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD, USA.
¹⁸ Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
¹⁹ Hôpital Saint Louis, Paris, France.
²⁰ Division of Hematology, Department of Medicine, Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
²¹ Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
²² Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
²³ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
²⁴ Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
²⁵ National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
²⁶ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
²⁷ Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
²⁸ Evergrande Center for Immunologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
²⁹ Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
³⁰ Division of Hematology, Department of Medicine, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
³¹ Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
³² The University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
³³ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
³⁴ Weill Cornell Medical College, New York, NY, USA.
³⁵ Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Health Research Institute La Fe, Valencia, Spain; and CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
³⁶ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
³⁷ Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
³⁸ Departments of Pathology & Laboratory Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
³⁹ Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
⁴⁰ University of Florence Medical School, Florence, Italy.

^# Contributed equally.

PMID: 36266326
DOI: 10.1038/s41375-022-01724-9

No abstract available

PubMed Disclaimer

Cited by

Frontline treatment options for higher-risk MDS: can we move past azacitidine?
Sallman DA, Xie Z. Sallman DA, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):65-72. doi: 10.1182/hematology.2023000421. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066872
Are We Ready For "Triplet" Therapy in Higher-Risk MDS?
Brunner AM, Platzbecker U, DeZern AE, Zeidan AM. Brunner AM, et al. Clin Hematol Int. 2023 Nov 3;5(4):88301. doi: 10.46989/001c.88301. eCollection 2023. Clin Hematol Int. 2023. PMID: 37933301 Free PMC article.
Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC.
Huber S, Baer C, Hutter S, Dicker F, Fuhrmann I, Meggendorfer M, Pohlkamp C, Kern W, Haferlach T, Haferlach C, Hoermann G. Huber S, et al. Leukemia. 2023 Oct;37(10):2138-2141. doi: 10.1038/s41375-023-02004-w. Epub 2023 Aug 12. Leukemia. 2023. PMID: 37573403 Free PMC article. No abstract available.
AML classification in the year 2023: How to avoid a Babylonian confusion of languages.
Huber S, Baer C, Hutter S, Dicker F, Meggendorfer M, Pohlkamp C, Kern W, Haferlach T, Haferlach C, Hoermann G. Huber S, et al. Leukemia. 2023 Jul;37(7):1413-1420. doi: 10.1038/s41375-023-01909-w. Epub 2023 Apr 29. Leukemia. 2023. PMID: 37120689 Free PMC article.

References

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. - PubMed - DOI
1. Malcovati L, Galli A, Travaglino E, Ambaglio I, Rizzo E, Molteni E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017;129:3371–8. - PubMed - PMC - DOI
1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19. - PubMed - PMC - DOI
1. Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549–56. - PubMed - PMC - DOI
1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. Blood. 2022:140;1200–28.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- Genetic Alliance
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Affiliations

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical